Tubo-on, Michael N.

HRN: 27-41-75  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/04/2025
CO-AMOXICLAV 625MG (TAB)
07/04/2025
07/10/2025
PO
625mg
BID
Lacerated Wound, Frontal Area
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: